Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia

Status Completed

Clinical Trial Summary

Acute lymphoblastic leukemia (ALL) accounts for about 20% of adult leukemias. Treatment results in adult ALL have lagged behind the improvements achieved in the pediatric population. A modified version of the Dana Farber Cancer Institute pediatric protocol is used to treat adult patients with ALL. The results seem to be superior to those reported with other adult protocols. However, there is limited data on the impact of such intensified approaches and resulting toxicities on the quality of life (QOL) of these survivors. Identifying important factors affecting the QOL may permit attempts at early interventions and may help to further modify the regimen and mitigate these adverse effects on QOL.

This study is evaluating the quality of life of long term survivors of adult ALL. It involves the patients filling out several questionnaires that are well-validated measures assessing various QOL issues of concern to these patients. The following questionnaires are used in this study:

- EORTC QLQ C30 to assess global health and major health domains

- Brief Pain Inventory (BPI)

- Personal Health Questionnaire (PHQ9) to assess psychosocial distress

- Functional Assessment of Cancer Therapy (FACT) Fatigue Questionnaire

- Peripheral Neuropathy Questionnaire

The data obtained from the questionnaires will be analyzed and the various domains of health will be quantified.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT01148927
Study type	Observational
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	N/A
Start date	November 2009
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Recruiting	`NCT05772000` - Clinical Significance of Occult Central Nervous System Localization
Recruiting	`NCT05618041` - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies	N/A
Active, not recruiting	`NCT03844048` - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase 3
Active, not recruiting	`NCT03114865` - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance	Phase 1/Phase 2
Not yet recruiting	`NCT06308588` - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Phase 2
Recruiting	`NCT05579132` - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia	Phase 1/Phase 2
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Terminated	`NCT02231853` - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections	Phase 1
Recruiting	`NCT04969601` - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings	Phase 1/Phase 2
Recruiting	`NCT06195891` - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome	Phase 1
Withdrawn	`NCT02815059` - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone	Phase 1
Completed	`NCT00390793` - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.	Phase 2
Recruiting	`NCT05866887` - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia	N/A
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting	`NCT06350994` - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn	`NCT04282174` - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies	Phase 2
Not yet recruiting	`NCT04488237` - Vitamin D and Methotrexate Adverse Effects
Completed	`NCT02544438` - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	Phase 1/Phase 2